Pfizer posts Q4 2025 net loss of $1.6 billion; reaffirms 2026 guidance
Pfizer reported fourth-quarter 2025 revenues of $17.6 billion, down 1% from a year earlier, and a net loss of $1.6 billion, or $(0.29) per share, after $4.4 billion in non-cash intangible asset impairment charges. Adjusted diluted EPS rose 5% to $0.66, and the company reaffirmed its full-year 2026 guidance of $59.5 to $62.5 billion in revenue and $2.80 to $3.00 in adjusted diluted EPS, which excludes share repurchases.
Key points
- Q4 2025 revenues $17.6 billion, down 1% reported and down 3% operationally; down 2% for full year 2025 to $62.6 billion
- Q4 2025 reported net loss of $1.6 billion, or $(0.29) per share, versus net income of $410 million, or $0.07 per share, a year earlier
- Q4 2025 adjusted diluted EPS $0.66 versus $0.63; full-year 2025 adjusted diluted EPS $3.22 versus $3.11
- 2026 guidance reaffirmed; no share repurchases expected in 2026, and $3.3 billion remains under the existing authorization
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 2:16 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 03, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.